Myofascial Pain Syndrome: An Update on Clinical Characteristics, Etiopathogenesis, Diagnosis, and Treatment.
Abstract
Myofascial pain syndrome (MPS) is a chronic regional pain condition characterized by trigger points-hyperirritable spots within taut bands of muscle fibers that cause both localized and referred pain. The pathogenesis, diagnostic criteria, and classification of MPS are still under investigation, which complicates the development of standardized treatment protocols. Although diagnostic tools have improved, MPS often remains underrecognized due to symptom overlap with other pain disorders, such as fibromyalgia, neuropathic pain, and joint disorders. Factors contributing to its onset and persistence include muscle overuse, postural imbalance, systemic conditions, and psychological and behavioral influences. This narrative review explores the primary risk factors, current hypotheses on pathogenesis, diagnosis and differential diagnosis, and both conventional and emerging treatments. Sufficient evidence supports the use of local anesthetic injections for MPS. Some evidence suggests that dry needling, acupuncture, magnetic stimulation, ultrasound therapy, laser therapy, extracorporeal shock wave therapy, and manual therapy may be effective, particularly compared to sham or placebo. However, non-steroidal anti-inflammatory drugs, diclofenac, botulinum toxin, and transcutaneous electrical nerve stimulation show insufficient evidence, while the effectiveness of muscle relaxants, antidepressants, gabapentin, opioids, topical lidocaine, capsaicin, EMLA cream, and kinesio taping remains inconclusive. Effective management of MPS requires a patient-centered approach that integrates empirically supported and evidence-based treatments tailored to individual needs. This review synthesizes the current understanding of MPS and highlights the need for high-quality research to improve clinical decision-making in managing this complex condition.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | Myofascial
|
scispacy | 1 | ||
| 해부 | muscle
|
scispacy | 1 | ||
| 해부 | muscle relaxants
|
scispacy | 1 | ||
| 약물 | lidocaine
|
리도카인 | dict | 1 | |
| 약물 | diclofenac
|
C0012091
diclofenac
|
scispacy | 1 | |
| 약물 | antidepressants
|
C0003289
Antidepressive Agents
|
scispacy | 1 | |
| 약물 | gabapentin
|
C0060926
gabapentin
|
scispacy | 1 | |
| 약물 | capsaicin
|
C0006931
capsaicin
|
scispacy | 1 | |
| 약물 | EMLA cream
|
scispacy | 1 | ||
| 약물 | non-steroidal anti-inflammatory
|
scispacy | 1 | ||
| 약물 | botulinum
|
scispacy | 1 | ||
| 약물 | opioids
|
scispacy | 1 | ||
| 약물 | EMLA
|
scispacy | 1 | ||
| 질환 | Myofascial Pain
|
C0553642
Soft tissue rheumatism
|
scispacy | 1 | |
| 질환 | MPS
→ Myofascial pain syndrome
|
C0016053
Fibromyalgia
|
scispacy | 1 | |
| 질환 | chronic regional pain
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | fibromyalgia
|
C0016053
Fibromyalgia
|
scispacy | 1 | |
| 질환 | neuropathic pain
|
C0027796
Neuralgia
|
scispacy | 1 | |
| 질환 | muscle overuse
|
scispacy | 1 | ||
| 질환 | dry
|
C0011682
Desiccation
|
scispacy | 1 | |
| 질환 | shock
|
C0036974
Shock
|
scispacy | 1 | |
| 기타 | muscle fibers
|
scispacy | 1 | ||
| 기타 | joint
|
scispacy | 1 | ||
| 기타 | MPS
→ Myofascial pain syndrome
|
scispacy | 1 |
MeSH Terms
Humans; Myofascial Pain Syndromes; Pain Management
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.